Get our latest issue now

available for iOS, Android & web

latest issue

Takeda and Amylin pull the plug on obesity combo drug

Daily News | August 05, 2011

Kevin Grogan

Takeda and Amylin pull the plug on obesity combo drug

Takeda and partner Amylin say they are discontinuing development of an investigational combination obesity therapy consisting of the latter's diabetes drug Symlin and metreleptin.

The companies say the joint decision is based on a "commercial reassessment" of the drug, which comprises Symlin (pramlintide), an analogue of amylin, and metreleptin, an analogue of  leptin. which had been in Phase II studies as a twice-a-day injection formulation. Takeda says the review took into account "a revised development plan as well as evolving dynamics within the obesity therapeutic area".

The companies said they will continue to evaluate other assets as potential candidates for obesity and related indications under the terms of their existing collaboration.

Christian Weyer, head of R&D at Amylin, said "the interplay of hormonal signals, such as amylin and leptin, plays a crucial role in the regulation of body weight” and "advances in peptide engineering and delivery may help us leverage this biology to develop a therapy with less frequent dosing".

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!